EURETINA 2023

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

08:30 AM

Duration 4mins Virtual

An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD

Gallego-Pinazo R, Weng, C, Souverain A, Stoilov I, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 4mins Virtual

Faricimab▼ Rapidly Improves Fluid Parameters in Patients With nAMD

Gale R, London N, Kotecha A, Willis J, Souverain A, Shildkrot E, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 4mins Virtual

Baseline characteristics and 3 month data from patients receiving faricimab▼ for nAMD or DME in the real-world VOYAGER study

Sheth V, Bailey C, Bengus M, Chaikitmongkol V, Chaudhary V, Chi G, Finger R, Gallego R, Gilberg R, Koh A, Ishida S, Lövestam M, Parravano M, Luna Pinto JD, Scheidl S, Schmitz-Valckenberg MS, Souied E, Guymer R

Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

Duration 4mins Virtual

Burden in the Clinical Management of Diabetic Macular Edema: A Multicenter Analysis in the UK

Peto T, Chen X, Talks S, Menon G, Ghanchi F, Shah P, Yang Q, Ferrara D, Adesanya L, Chi G

Ophthalmology | Diabetic Macular Edema

Duration 4mins Virtual

Changes in Intraocular Ang-2 and VEGF-A Following Faricimab▼ Treatment in nAMD and DME

Cheung G, Bogman K, Diack C, Stoilov I

Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

Duration 4mins Virtual

Deep learning segmentation of foveal avascular zone in optical coherence tomography angiography of nonproliferative diabetic retinopathy

Benmansour F, Camino A, Wang Z, Basu Bal A, Carano R, Ferrara D

Ophthalmology | Diabetic Retinopathy

Duration 4mins Virtual

Fibrosis Characterisation and Prevention in nAMD: Identification of Subretinal Triggers, Cell Types Responsible and Inhibitors Using Improved Tools

Westenskow P, Ozaki E, Doyle S, Roubeix C

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 4mins Virtual

Personalised Faricimab▼ Dosing Increased the Proportion of Patients With nAMD Achieving Q16W Dosing in Year 2 of TENAYA/LUCERNE, While Maintaining Functional and Anatomical Outcomes

Ambresin A, Kotecha A, Willis J, Souverain A, Shildkrot E, Swaminathan B, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 4mins Virtual

Efficacy, durability, and safety of faricimab▼ in neovascular age-related macular degeneration (nAMD): 48-week results from the China subpopulation of the phase 3 LUCERNE trial

Chen Y, Kotecha A, Willis J, Liu R, Li S, Zhang L, Zhang M, Sun D

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 4mins Virtual

Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pavilion Trial

Wykoff C, Chang M, Emanuelli A, Holekamp N, Latkany P, Malhotra V, Brittain C, Howard D, Santhanakrishnan A, Wetzel-Smith M, Quezada-Ruiz C, Pieramici D

Ophthalmology | Diabetic Macular Edema - Diabetic Retinopathy

Duration 4mins Virtual

Postoperative Monitoring and Long-term Follow-up: A PDS-treated Patient Case From the Ladder Phase 2 Trial Continuing into the Portal Extension Trial

Graff J, Heinrich D, Blotner S, Cavichini Cordeiro M, Gune S, Singh N

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 4mins Virtual

Refill-Exchange Procedure for the Port Delivery System with Ranibizumab: Optimisation and Enhanced Training

Becker M, Colina J, Graff J, Kitchens J, Thompson J, Malhotra V, Menezes A, Patel S, Singh N, Utley S, Vicente A, Jaycock P

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 4mins Virtual

FARWIDE-DME: early treatment patterns of faricimab▼ among DME patients in the UK

Bailey C, Peto T, Downey L, Kiire C, Pearce I, Reynolds R, Sivaprasad S, Chi G, James N, Downey A, Shah P, Dodds M, Dayal P

Ophthalmology | Diabetic Macular Edema

Duration 4mins Virtual

Visual Loss in Geographic Atrophy: A Comprehensive Exploratory Analysis of Function and Morphology From the Lampalizumab Trial Programme

Ferrara D, Anegondi N, Steffen V, Chakravarthy U

Ophthalmology | Geographic Atrophy

Duration 4mins Virtual

Investigating the Burden of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment on Recipients and Caregivers in North America and Europe

Gale R, Tabano D, Cox O, Garmo V, Ahmed A, Hill S, Patel N, Watane A

Ophthalmology | Diabetic Macular Edema

12:19 PM

Duration 6mins Emerald Room

Comparative Efficacy of Faricimab▼ for the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis

Holekamp N, Mar F, Gibson K

Ophthalmology | Diabetic Macular Edema

09:07 AM

Duration 6mins Room E102

The Relevance of Clinical and Imaging Features in Artificial Intelligence-Based Prediction of Geographic Atrophy Progression

Ferrara D, Cluceru J, Slama O, Anegondi N, Gao S, Friesenhahn M, Rabe C

Ophthalmology | Geographic Atrophy

09:16 AM

Duration 5mins Speakers Corner

Socio-economic deprivation and diabetic macular edema: health equity improvements driven by faricimab in an aggregate distributional cost-effectiveness analysis from an English NHS perspective

Gale R, Meunier A, Opeifa O, Longworth L, Cox O, Buhrer C, Durand-Zaleski I, Kelly S

Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

11:07 AM

Duration 6mins Room E102

Port Delivery System With Ranibizumab in Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pagoda Trial

Graff J, Marcus D, Campochiaro P, Rahman S, Malhotra V, Latkany P, Gune S, DeGraaf S, Bobbala A, Rabena M, Quezada-Ruiz C, Khanani A

Ophthalmology | Diabetic Macular Edema - Diabetic Retinopathy

11:13 AM

Duration 6mins Room E102

FARETINA-DME-six-month treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab▼: an IRIS (tm) Registry analysis

Bailey C, Tabano D, Borkar D, Garmo V, Ahmed A, Myers R, LaPrise A, Ali F, Leng T, Singh R

Ophthalmology | Diabetic Macular Edema

11:19 AM

Duration 6mins Room E102

Automated Segmentation of Hyperreflective Foci in DME Shows Greater Volume Reduction in Eyes Treated With Faricimab▼ Compared to Aflibercept in the Phase 3 YOSEMITE and RHINE Clinical Trials

Chakravarthy U, Maunz A, Von Schulthess E, Patel K, Bachmeier I, Jones I, Cohen Y, Gibson K, Willis J, Glittenberg C, Fauser S

Ophthalmology | Diabetic Macular Edema

12:18 PM

Duration 6mins Grand Auditorium

The Potential for Q20W Dosing With Faricimab▼ and Extended Treatment Outcomes in Neovascular Age-Related Macular Degeneration: a Post Hoc Analysis of the Pivotal TENAYA/LUCERNE Trials

Ambresin A, Koh A, Singer M, Tadayoni R, Hill L, Souverain A, Kotecha A, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

01:03 PM

Duration 6mins E102

Optimisation of the Port Delivery System with Ranibizumab (PDS): Key Steps and Impact on Patient Outcomes

Hillier R, Vicente A, Jaycock P, Quezada-Ruiz C, Singh N

Ophthalmology | Neovascular Age Related Macular Degeneration

03:46 PM

Duration 6mins Room E102

Faricimab▼ Personalised Treat-and-Extend–Based Dosing Dynamics in Patients With DME

Figueroa M, Pearce I, Lim J, Gibson K, Jain N, Souverain A, Yang M, Willis J, Haskova Z

Ophthalmology | Diabetic Macular Edema

09:25 AM

Duration 6mins Room E102

Faster Time to Retinal Fluid Control With Faricimab▼ vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials – Lanzetta P

Lanzetta P, Rachitskaya A, Camino A, Gibson K, Mar F, Shildkrot E, Tang Y, Willis J, Haskova Z

Ophthalmology | Diabetic Macular Edema

Duration 6mins Room E102

Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With Diabetic Macular Edema

Sivaprasad S, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, Wang T, Haskova Z, Amador M, Mar F, Goldberg R

Ophthalmology | Diabetic Macular Edema

12:19 PM

Duration 6mins Room E102

A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study

Pavesio C, Sharma S, Suhler E, Lin P, Pauly-Evers M, Willen D, Peck R, Storti F, Rauhut S, Gott T, Passemard B, Macgregor L, Haskova Z, Silverman D, Fauser S, Mesquida M

Ophthalmology | Uveitis - Diabetic Macular Edema

12:36 PM

Duration 5mins Speakers Corner

FARWIDE-nAMD: early treatment patterns of faricimab▼ among neovascular age-related macular degeneration (nAMD) patients in the UK

Talks J, De Salvo G, Patel P, de Silva S, Gale R, Varma D, McKibbin M, James N, Downey A, Shah P, Dodds M, Dayal P, Chi G

Ophthalmology | Neovascular Age Related Macular Degeneration

03:30 PM

Duration 6mins E103/104

Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Pagoda Trial of Diabetic Macular Edema and the Phase 3 Pavilion Trial of Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

Dhoot D, Ding HT, Hyung S, Latkany P, Maass K, Rahman S, Hsu J

Ophthalmology | Diabetic Macular Edema - Diabetic Retinopathy

03:43 PM

Duration 6mins Room E103/104

Efficacy, durability, and safety of faricimab▼ in diabetic macular edema (DME): 1-year results from China subpopulation of phase 3 RHINE trial

Li X, Sun X, Jiang Q, Liu X, Idowu O, Liu R, Liu W, Tang Y, Willis J, Zhang L, Kotecha A

Ophthalmology | Diabetic Macular Edema

I am a healthcare professional

Notice

Cookies

External site

EURETINA 2023